The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Intra-Arterial Bone Marrow Mononuclear Cells in Ischemic Stroke: A Pilot Clinical Trial
Abstract
Background and Purpose—: Bone marrow mononuclear cell (BM-MNC) intra-arterial transplantation improves recovery in experimental models of ischemic stroke. We aimed to assess the safety, feasibility, and biological effects of autologous BM-MNC transplantation in patients with stroke. Methods—: A single-blind (outcomes assessor) controlled Phase I/II trial was conducted in patients with middle cerebral artery stroke. Autologous BM-MNCs were injected intra-arterially between 5 and 9 days after stroke. Follow-up was done for up to 6 months and blood samples were collected for biological markers. The primary outcome was safety and feasibility of the procedure. The secondary outcome was improvement in neurological function. Results—: Ten cases (BM-MNC-treated) and 10 control subjects (BM-MNC-nontreated) were consecutively included. Mean National Institutes of Health Stroke Scale before the procedure was 15.6. Mean BM-MNCs injected were 1.59×10 8 . There was no death, stroke recurrence, or tumor formation during follow-up, although 2 cases had an isolate partial seizure at 3 months. After transplantation, higher plasma levels of beta nerve growth factor (β-nerve growth factor) were found compared with control subjects ( P =0.02). There were no significant differences in neurological function at 180 days. A trend to positive correlation between number of CD34+ cells injected and Barthel Index was found ( r =0.56, P =0.09). Conclusions—: Intra-arterial BM-MNC transplantation in subacute ischemic stroke is feasible and seems to be safe. Larger randomized trials are needed to confirm the safety and elucidate the efficacy of BM-MNC transplantation. Clinical Trial Registration-URL—: www.clinicaltrials.gov . Unique identifier: NCT00761982.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neurorestorative therapies for stroke: underlying mechanisms and translation to the clinic
Zhang, Z. G., & Chopp, M. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70061-4 · Cited by 596
Cited by
Novel Stroke Therapeutics: Unraveling Stroke Pathophysiology and Its Impact on Clinical Treatments
George, P. M., & Steinberg, G. K. (2015) · Neuron · doi:10.1016/j.neuron.2015.05.041 · Cited by 393
Immune interventions in stroke
Fu, Y., Liu, Q., Anrather, J., & Shi, F.-D. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.144 · Cited by 383
Mesenchymal Stromal Cell Therapeutic Delivery: Translational Challenges to Clinical Application
Caplan, H., Olson, S. D., Kumar, A., George, M., Prabhakara, K. S., Wenzel, P., Bedi, S., Toledano-Furman, N. E., Triolo, F., Kamhieh-Milz, J., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01645 · Cited by 306
Dabrowska, S., Andrzejewska, A., Lukomska, B., & Janowski, M. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1571-8 · Cited by 298
Inflammatory Disequilibrium in Stroke
Petrovic-Djergovic, D., Goonewardena, S. N., & Pinsky, D. J. (2016) · Circulation Research · doi:10.1161/circresaha.116.308022 · Cited by 265
Metadata
- Authors
- Moniche, F., Gonzalez, A., Gonzalez-Marcos, J.-R., Carmona, M., Piñero, P., Espigado, I., Garcia-Solis, D., Cayuela, A., Montaner, J., Boada, C., Rosell, A., Jimenez, M.-D., Mayol, A., & Gil-Peralta, A.
- Venue
- Stroke
- Published
- 2012-08
- Volume
- 43
- Issue
- 8
- Pages
- 2242-2244
- ISSN
- 0039-2499 (ISSN-L)
- 1524-4628
- OpenAlex
- W1999494893
- Cited by
- 226
- References
- 1
- FWCI
- 9.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intra-Arterial Bone Marrow Mononuclear Cells in Ischemic Stroke: A Pilot Clinical Trial. https://app.cochat.ai/papers/10.1161/strokeaha.112.659409
- The paper
- Moniche, F., Gonzalez, A., Gonzalez-Marcos, J.-R., Carmona, M., Piñero, P., Espigado, I., Garcia-Solis, D., Cayuela, A., Montaner, J., Boada, C., Rosell, A., Jimenez, M.-D., Mayol, A., & Gil-Peralta, A. (2012). Intra-Arterial Bone Marrow Mononuclear Cells in Ischemic Stroke: A Pilot Clinical Trial. Stroke. https://doi.org/10.1161/strokeaha.112.659409
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.